Literature DB >> 22874658

Improved statistical power of Alzheimer clinical trials by item-response theory: proof of concept by application to the activities of daily living scale.

M Colin Ard1, Douglas R Galasko, Steven D Edland.   

Abstract

Discovery of effective treatment for Alzheimer disease (AD) depends upon the availability of outcome measures that exhibit good sensitivity to rates of longitudinal decline on global functional performance. The Alzheimer's Disease Cooperative Study-Activities of Daily Living inventory (ADCS-ADL) is a frequently used functional endpoint in clinical trials for AD that assesses patient functional ability on the basis of informant ratings of patient performance on a variety of everyday tasks. Previous research has shown that the items comprising the ADCS-ADL are sensitive to characteristic longitudinal trajectories in AD. However, standard procedures for combining information from individual items into an overall test score may not make full use of the information provided by informant responses. The current study explored an application of item-response theory (IRT) techniques to the calculation of test scores on the ADCS-ADL. Using data from 2 ADCS clinical trials on mild-to-moderate AD patients we found that IRT based scoring increased sensitivity to change in functional ability and improved prospective statistical power of the ADCS-ADL as an outcome measure in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22874658      PMCID: PMC4362713          DOI: 10.1097/WAD.0b013e318265bcc1

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  6 in total

1.  ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials.

Authors:  Douglas Galasko; David A Bennett; Mary Sano; Daniel Marson; Jeff Kaye; Steven D Edland
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Oct-Dec       Impact factor: 2.703

2.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

Authors:  Joseph F Quinn; Rema Raman; Ronald G Thomas; Karin Yurko-Mauro; Edward B Nelson; Christopher Van Dyck; James E Galvin; Jennifer Emond; Clifford R Jack; Michael Weiner; Lynne Shinto; Paul S Aisen
Journal:  JAMA       Date:  2010-11-03       Impact factor: 56.272

3.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  D Galasko; D Bennett; M Sano; C Ernesto; R Thomas; M Grundman; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

4.  Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

Authors:  Linda K McEvoy; Steven D Edland; Dominic Holland; Donald J Hagler; J Cooper Roddey; Christine Fennema-Notestine; David P Salmon; Alain K Koyama; Paul S Aisen; James B Brewer; Anders M Dale
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

Review 5.  Power calculations for clinical trials in Alzheimer's disease.

Authors:  M Colin Ard; Steven D Edland
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Authors:  Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

  6 in total
  7 in total

1.  Modeling a Composite Score in Parkinson's Disease Using Item Response Theory.

Authors:  Gopichand Gottipati; Mats O Karlsson; Elodie L Plan
Journal:  AAPS J       Date:  2017-02-28       Impact factor: 4.009

2.  Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.

Authors:  Holly Posner; Rosie Curiel; Chris Edgar; Suzanne Hendrix; Enchi Liu; David A Loewenstein; Glenn Morrison; Leslie Shinobu; Keith Wesnes; Philip D Harvey
Journal:  Innov Clin Neurosci       Date:  2017-02-01

3.  An item response theory based integrated model of headache, nausea, photophobia, and phonophobia in migraine patients.

Authors:  Dongwoo Chae; Kyungsoo Park
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-24       Impact factor: 2.745

4.  Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling.

Authors:  Sebastian Ueckert; Elodie L Plan; Kaori Ito; Mats O Karlsson; Brian Corrigan; Andrew C Hooker
Journal:  Pharm Res       Date:  2014-03-05       Impact factor: 4.200

5.  Is Barthel Index Suitable for Assessing Activities of Daily Living in Patients With Dementia?

Authors:  Yayan Yi; Lin Ding; Huangliang Wen; Jialan Wu; Kiyoko Makimoto; Xiaoyan Liao
Journal:  Front Psychiatry       Date:  2020-05-08       Impact factor: 4.157

6.  Optimal composite scores for longitudinal clinical trials under the linear mixed effects model.

Authors:  M Colin Ard; Nandini Raghavan; Steven D Edland
Journal:  Pharm Stat       Date:  2015-07-30       Impact factor: 1.894

7.  Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia.

Authors:  Ehj Krekels; A M Novakovic; A M Vermeulen; L E Friberg; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.